LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U. obesity biotech Metsera marks an aggressive shift ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

The consensus estimate for Q3 2025 revenue is $214.81 million, and the earnings are expected to come in at $0.52 per share.

Wall Street eyed a US-China truce agreed by Trump and Xi, cooling hopes for a December rate cut and the next batch of Big ...

The average long-term mortgage rate dropped to 6.17% from 6.19% last week, mortgage buyer Freddie Mac said Thursday. A year ...

AMD (NASDAQ:AMD) has transformed remarkably in the artificial intelligence (AI) space. Just a few years ago, the company had ...

Centene on Wednesday raised its 2025 adjusted profit forecast and said it looks to grow its earnings next year, sending ...

(Reuters) -Drug distributor Cardinal Health raised its annual adjusted profit forecast on Thursday after beating estimates ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the ...

American farmers welcomed China's promise to buy some of their soybeans, but they cautioned this won't solve all their ...